Histogenics Corporation to Present at the 2017 Cell & Gene Meeting on the Mesa

WALTHAM, Mass., Sept. 26, 2017 -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leading cell therapy company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will be participating in a panel discussion on tissue engineering on Wednesday, October 4, 2017 at 10:45 am PT and presenting a corporate overview during the meeting’s Partnering Forum on Wednesday, October 4, 2017, at 3:15 pm PT. 

The conference will be held October 4-6 at the Estancia La Jolla Hotel & Spa in La Jolla California and will feature a two-day Partnering Forum, a Public Forum lecture and a full-day Scientific Symposium. The Cell & Gene Meeting on the Mesa is organized by the Alliance for Regenerative Medicine (ARM) and the Sanford Consortium for Regenerative Medicine.

This presentation will be webcast live and may be accessed by visiting the Investor Relations section of Histogenics’ website at www.histogenics.com or at www.meetingonthemesa.com/webcast/ and will also be published on ARM’s website shortly after the event.  The webcast will be archived and available on Histogenics’ website for 45 days following the conference.

About Histogenics Corporation

Histogenics is a leading cell therapy company developing and commercializing novel tissue therapies that may offer more rapid and durable recoveries for patients with pain and loss of function due to musculoskeletal conditions. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering and bioadhesives to create tissue ex-vivo.  Histogenics’ first investigational product candidate, NeoCart^® is designed to treat cartilage defects in the knee.  The Company recently completed enrollment of its NeoCart Phase 3 clinical trial and expects to report top-line data in the third quarter of 2018.  NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage.  As a result, NeoCart is the only product in development or on the market with a one-year primary superiority endpoint as compared to the standard of care.  There are more than 500,000 or more knee cartilage procedures in the United States each year, with many healthy active adults avoiding treatment as they seek other alternatives. Left untreated, even a small cartilage defect can expand in size and progress to debilitating osteoarthritis, ultimately necessitating a joint replacement procedure.  Osteoarthritis is more common in adults over the age of 50, but the condition and precursors of the condition can be observed much earlier, and cartilage damage is believed to be one of the leading contributors of this disease.  For more information, please visit www.histogenics.com.

Contact:

Investor Relations
Tel: +1 (781) 547-7909
[email protected]